Jul 31 |
CareDx (CDNA) Q2 Earnings and Revenues Beat Estimates
|
Jul 31 |
CareDx raised 2024 revenue estimates, Q2 beats lead shares 24% higher
|
Jul 31 |
CareDx Non-GAAP EPS of $0.25 beats by $0.39, revenue of $92.3M beats by $24.45M
|
Jul 31 |
CareDx: Q2 Earnings Snapshot
|
Jul 31 |
CareDx Reports Second Quarter 2024 Results and Increases Revenue Guidance
|
Jul 31 |
Investing in CareDx (NASDAQ:CDNA) a year ago would have delivered you a 79% gain
|
Jul 30 |
CareDx Q2 2024 Earnings Preview
|
Jul 16 |
CareDx to Report Second Quarter 2024 Financial Results
|
Jul 15 |
CareDx: Benefiting From Some Certainty
|
Jun 3 |
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
|